With inflation, interest rates and global growth expectations all pulling markets in different directions, many investors are looking for companies where analysts still see clear earnings growth and balance sheets that can support it. The Healthy high growth potential screener focuses on exactly that. It highlights stocks where analysts expect earnings expansion over the next 3 years, alongside an acceptable financial position. In this article, three of the best stocks from this screener will be highlighted, giving you a focused shortlist to research further if you are aiming to build exposure to potential earnings growth while keeping an eye on financial quality.

Liquidia (LQDA)

Overview: Liquidia is a US biopharmaceutical company focused on treatments for rare cardiopulmonary diseases, led by its inhaled treprostinil therapy YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, alongside late stage candidate L606 and its PRINT particle engineering technology platform.

Operations: Liquidia generates its US$288.1 million in revenue from pharmaceuticals, primarily in the United States.

Market Cap: US$6.6b

Investors looking at Liquidia are seeing a company that is moving from development stage to commercial execution, with YUTREPIA already contributing to current results. The pipeline, including L606 and additional PRINT based applications, offers potential follow on revenue streams, while recent index inclusion and multiple analyst price target increases indicate rising institutional interest. At the same time, leverage, funding risk and recent insider selling mean the story is not without pressure points. Investors may wish to consider how YUTREPIA’s adoption, payer access developments and manufacturing expansion balance against those risks and how that fits within the valuation currently implied by analyst coverage.

Liquidia’s shift from pure pipeline story to real YUTREPIA revenue has many investors focused on growth, but the real tension is how that trajectory stacks up against the risks that still sit in the background, which is exactly what the 3 key rewards and 1 important warning sign quietly surfaces before one key twist changes the picture

Iovance Biotherapeutics (IOVA)

Overview: Iovance Biotherapeutics is a commercial stage biopharma company that develops and sells personalized cell therapies, led by Amtagvi and Proleukin, to treat metastatic melanoma and other hard to treat solid tumors in the United States and internationally.

Operations: Iovance Biotherapeutics generates about US$285.6 million in revenue from its autologous TIL based therapies, with roughly US$281.0 million from the United States and US$4.6 million from the rest of the world.

Market Cap: US$1.9b

Iovance Biotherapeutics operates in one of the most closely watched areas in oncology, with Amtagvi already approved in multiple regions. The company is still loss making, relies heavily on a small number of products and has used substantial external funding and new share issuance, so execution risk and dilution remain key considerations. For investors who can handle volatility, the mix of a first mover position in solid tumor cell therapy, a growing TIL pipeline and a stock that screens as deeply discounted on several metrics raises the question of whether the current valuation reflects the range of potential outcomes for Amtagvi and future approvals.

Iovance Biotherapeutics sits at the crossroads of an early commercial rollout and a stock that screens as deeply discounted, which is exactly where the analysis report for Iovance Biotherapeutics starts to reveal how the first mover TIL story and funding risks really fit together

Hamilton Lane (HLNE)

Overview: Hamilton Lane is a Philadelphia based asset manager that builds and runs private markets funds and customized portfolios for institutions and wealth clients, giving them access to private equity, private credit, infrastructure and other alternative investments across regions and sectors.

Operations: Hamilton Lane generates about US$759.0 million in revenue from asset management, with roughly US$310.4 million from the United States and US$448.6 million from other countries.

Market Cap: US$4.1b

Hamilton Lane may appeal to investors who want exposure to private markets growth through a profitable, fee based asset manager rather than individual deals. The company reports fee generating assets, high margins and a return on equity above 26%, supported by evergreen funds, tokenized vehicles and a growing global client base. At the same time, high executive pay, fee pressure, rising regulatory costs and 100% reliance on wholesale funding mean the business does not resemble a low risk annuity stream. For readers weighing these factors against analyst expectations for faster earnings growth and a wide gap to some valuation estimates, there is more detail in the Hamilton Lane analysis that follows.

Hamilton Lane’s fee-rich private markets engine and 26% return on equity raise a clear question: does the current price fully reflect that earnings profile or what the analysis report for Hamilton Lane shows is sitting underneath?

The three stocks covered here are only a starting point, and the full Healthy high growth potential screener has surfaced 1,493 more companies with equally compelling earnings and balance sheet stories that could fit what you are looking for in this market. It is worth seeing the complete Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas instead of a long, unfocused watchlist.

Take Control of Your Investment Journey

If Liquidia or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Stock stories move fast, and the best breakout setups often get caught once momentum is already flying. Scan these fresh ideas while it matters and aim to get in earlier in the move.

• Spot resilient compounders early by scanning a curated 69 resilient stocks with low risk scores that is built to keep moving even when markets feel choppy, so you are not reacting after the move.
• Hunt for cash-generating AI leaders using the hand picked 61 profitable AI stocks that aren't just burning cash to focus on companies where revenue matters, not just headlines and hype cycles that fade.
• Position ahead of infrastructure tailwinds by reviewing a tightly filtered 33 power grid technology and infrastructure stocks and looking for stocks tied to grid upgrades before the crowd chases the theme.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.